Portal Hypertension Drug Development Pipeline Study, H1 2018 - ResearchAndMarkets.com

DUBLIN--()--The "Portal Hypertension: Drug Development Pipeline Study, H1 2018" report has been added to ResearchAndMarkets.com's offering.

Portal Hypertension pipeline comprises of 8 drugs under development as of March 2018. Of these, 2 drugs are in Phase 1 and 5 drugs in phase 2 with no drugs in Phase 3. Further, 1 drug is in Pre-IND stage.

18 companies are developing the pipeline for Portal Hypertension. Of this, LinXis B.V. has the most recent stage drug in pipeline. 8 different mechanisms are being targeted for treatment of the condition.

Portal hypertension is the major cause for morbidity and mortality witnessed in patients suffering from liver cirrhosis. The condition is characterized by an increase in blood pressure levels in the portal venous system. It is one of the catastrophic complications associated with liver cirrhosis. As the vessels in the liver are blocked, blood does not smoothly pass through liver, resulting in elevated blood pressure. This results in growth of large and swollen veins in esophagus, stomach, rectum and umbilical areas.

Scope:

  • All latest industry developments and their impact on projects and companies
  • Complete overview of global Portal Hypertension therapy options and treatments
  • The pipeline study reviews drug details for Portal Hypertension by developing companies, institutions, mechanism of action, Target, Route, Phase (pre-clinical/ Discovery, Phase 1, Phase 2, Phase 3, Pre-Registration, IND/ NDA), molecule
  • Mergers, Acquisitions, licensing, co-development and project acquisition news for Portal Hypertension market
  • Portal Hypertension drugs being developed in combination with other drugs are also detailed
  • Company wise drugs listed with their current status, partners and news updates

Products Mentioned:

  • Emricasan
  • Portaban
  • GR-MD-02
  • Udenafil
  • LxL-001
  • Serelaxin
  • ONO 1266
  • FE 204205

Companies Mentioned

  • Bristol-Myers Squibb
  • Conatus Pharmaceuticals
  • Conatus Pharmaceuticals
  • Cumberland Pharmaceuticals
  • Dr. Falk Pharma GmbH
  • Ferring Pharmaceuticals
  • Galectin Therapeutics
  • Groningen Research Institute of Pharmacy
  • LinXis B.V.
  • LinXis B.V.
  • Mezzion Pharma Co. Ltd.
  • NHS Lothian
  • Novartis Pharmaceuticals
  • Ono Pharmaceutical
  • Providence Cancer Center
  • Providence Health & Services
  • University of Bonn
  • University of Edinburgh

For more information about this report visit https://www.researchandmarkets.com/research/247kh5/portal?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Drug Discovery, Cardiovascular Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Drug Discovery, Cardiovascular Drugs